ThermoGenesis Holdings, Inc. THMO
- Market cap
- $1.1M
- P/E
- 0.0×
Follow THMO
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 737.10 | 1,179.00 | 94.50 | 105.75 | 73.35 | 43.46 | 2.67 | 0.51 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 3,325.50 | 2,898.00 | 1,764.00 | 315.00 | 638.10 | 200.25 | 55.35 | 6.67 |
High Price
|
|||
| — | — | 89 | 70 | 53 | 50 | 41 | 40 | 41 | 25 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 12 | 12 | 10 | 13 | 10 | 9 | 10 | 9 |
Revenue
|
|||
| — | — | 23.00% | 35.84% | 22.67% | 43.66% | 12.92% | 37.58% | 25.85% | 20.44% |
Gross Margin
|
|||
| — | — | (19) | (10) | (46) | (10) | (17) | (12) | (12) | (19) |
EBT
|
|||
| — | — | (155.82%) | (83.29%) | (472.19%) | (77.40%) | (172.53%) | (127.82%) | (112.68%) | (200.31%) |
EBT Margin
|
|||
| — | — | (19) | 0 | (41) | (10) | (17) | (12) | (12) | (19) |
Net Income
|
|||
| — | — | 1 | 0 | 2 | 3 | 6 | 4 | 4 | 9 |
Depreciation
|
|||
| — | — | 48.57 | 534.49 | 236.48 | 207.75 | 69.90 | 35.46 | 19.03 | 3.99 |
Revenue/Sh
|
|||
| — | — | (75.70) | (202.50) | (972.97) | (151.35) | (117.12) | (43.24) | (20.45) | (7.59) |
Earnings/Sh
|
|||
| — | — | (39.19) | (147.42) | (170.73) | (51.91) | (103.25) | (25.26) | (13.22) | (1.57) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | 0.00 | (30.27) | (2.90) | (0.16) | (0.35) | (0.73) | (0.73) |
Capex/Sh
|
|||
| — | — | (39.19) | (147.42) | (201.00) | (54.81) | (103.41) | (25.61) | (13.94) | (2.30) |
Free CF/Sh
|
|||
| — | — | 131.40 | 1,476.09 | 164.57 | 14.59 | 42.11 | 12.96 | 6.03 | (1.51) |
Book Value/Sh
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 2.34 | 2.23 | 0.51 | 0.95 | 1.35 | 1.28 | 0.19 | 0.14 |
PS Ratio
|
|||
| — | — | 0.97 | 0.93 | 0.73 | 13.57 | 2.23 | 3.51 | 0.59 | 0.00 |
PB Ratio
|
|||
| — | — | 2.17 | 2.46 | 0.38 | 1.01 | 1.29 | 1.49 | 0.14 | 0.25 |
EV/Sales
|
|||
| — | — | (1.96) | (4.85) | (0.45) | (3.84) | (0.87) | (2.07) | (0.18) | (0.44) |
EV/FCF
|
|||
| — | — | (10) | (3) | (7) | (3) | (14) | (7) | (7) | (4) |
Op' Cash Flow
|
|||
| — | — | (1) | 0 | (1) | 0 | 0 | 0 | 0 | (2) |
Capex
|
|||
| — | — | (10) | (3) | (8) | (3) | (14) | (7) | (8) | (5) |
FCF
|
|||
| — | — | 7 | 6 | 2 | 3 | 9 | 9 | (1) | (7) |
Working Cap'
|
|||
| — | — | 2 | 7 | 1 | 5 | 7 | 9 | 4 | — |
Total Debt
|
|||
| — | — | (3) | 3 | (1) | 1 | (1) | 2 | (1) | (2) |
Net Debt
|
|||
| — | — | 32 | 33 | 7 | 1 | 6 | 3 | 3 | (4) |
Sh' Equity
|
|||
| — | — | (37.25%) | (9.31%) | (120.86%) | (63.68%) | (90.65%) | (54.82%) | (56.30%) | (117.41%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | (494.38%) | (175.04%) | (104.19%) | (84.29%) | (139.63%) | 0.00% |
ROIC
|
|||
| — | — | (57.60%) | (14.26%) | (198.86%) | (248.38%) | (481.90%) | (245.58%) | (335.42%) | 13,773.95% |
ROE
|
|||
ThermoGenesis Holdings, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DYNTQ Dynatronics Corporation | $1.2M | 0.0× | Compare |
| SSKN Strata Skin Sciences, Inc. | $1.0M | 0.0× | Compare |
| FEED ENvue Medical, Inc. | $950.0K | 0.0× | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PFSA PROFUSA, Inc. | $1.6M | 0.0× | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | 0.0× | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | 0.0× | Compare |
| BIOLQ Biolase, Inc. | $2.3M | 0.0× | Compare |
ThermoGenesis Holdings, Inc. (THMO) key facts
- ThermoGenesis Holdings, Inc. (THMO) is a Medical Devices company in the Healthcare sector.
- ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022.
- Return on equity was 13,774.0% and debt-to-equity 0.00.
ThermoGenesis Holdings, Inc. (THMO) Latest News
27 Feb
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) may be close to turning a profit, with analysts predicting breakeven in 2023. The potential for ThermoGenesis Holdings to reach profitability in the near future could significantly impact its future performance and market sentiment.
8 Dec
ThermoGenesis Holdings' CEO compensation and performance analyzed ahead of AGM. CEO compensation and company performance could be influenced by upcoming AGM.
14 Nov
ThermoGenesis Holdings, Inc. reported Q3 2023 financial results, highlighting transition to CDMO services for cell gene therapy market. Transition to CDMO services and potential impact on cell gene therapy market could significantly alter company's trajectory.
ThermoGenesis Holdings, Inc. launched a CDMO service for cell gene therapy market, aiming to provide turnkey solutions for early and mid-stage companies. The launch of CDMO services and proprietary CAR-TXpress platform is expected to significantly impact the company's future performance and competitive positioning.
13 Nov
ThermoGenesis Holdings announces Q3 2023 financial results and corporate update. Moderately noticeable influence expected on financial performance and competitive positioning.
8 Nov
ThermoGenesis Holdings to announce Q3 financial results and corporate update. The financial results and strategic update may moderately influence the company's performance and competitive positioning.
26 Oct
ThermoGenesis is opening a new facility in Greater Sacramento. The new facility may moderately influence ThermoGenesis' competitive positioning and product innovation.
6 Sep
ThermoGenesis Holdings to present at H.C. Wainwright 25th Annual Global Investment Conference. Presentation at the conference may moderately influence financial performance and competitive positioning.
12 Aug
ThermoGenesis Holdings, Inc. reported Q2 2023 financial results, focusing on transition to CDMO cell manufacturing for cell and gene therapy market. Transition to CDMO cell manufacturing and potential impact on cell and gene therapy market could significantly alter company's trajectory and investor sentiment.
11 Aug
ThermoGenesis Holdings, Inc. discusses progress in transitioning to a CDMO cell manufacturer for cell and gene therapy market, highlighting the completion of GMP facility in Sacramento. The article describes significant strategic moves and developments that are expected to have a profound influence on ThermoGenesis Holdings, Inc.'s future trajectory and market performance.
10 Aug
ThermoGenesis Holdings reported Q2 2023 financial results and corporate update. Financial results and strategic updates may moderately influence company's future.
8 Aug
ThermoGenesis Holdings to announce financial results for the second quarter ended June 30, 2023 and provide a corporate strategic update. The announcement of financial results and corporate strategic update can significantly impact the company's future trajectory and investor sentiment.
17 Jul
ThermoGenesis appoints Dr. Biao Xi and Dr. James Xu to its Board of Directors. The appointments of highly experienced individuals to the Board are expected to significantly strengthen the company's strategic direction and competitive positioning.
7 Jul
ThermoGenesis Holdings, Inc. (NASDAQ:THMO) may reach breakeven soon, analysts predict profitability in 2024. The article discusses significant potential impact on ThermoGenesis Holdings' future profitability and market performance.
16 May
ThermoGenesis Holdings, Inc. reported on their Q1 2023 earnings call, highlighting progress towards becoming a CDMO for cell and gene therapy markets. The company's strategic shift towards CDMO services in the growing cell and gene therapy industry is expected to have a significant impact on their future performance and market positioning.
15 May
ThermoGenesis Holdings announces Q1 2023 financial results and corporate update. The financial results and corporate update may moderately influence key areas like financial performance and competitive positioning.
10 May
ThermoGenesis Holdings to announce financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update. The announcement of financial results and strategic update could significantly impact ThermoGenesis Holdings' future trajectory and market performance.